GlassScriptPhysician profile
Chimene L Cobb
NPI 1871263350
$1,618.92
in general payments reported to CMS, 2019-2025
13 companies · $214 in 2025
The $214 reported for 2025 was more than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $252 · 2022: $876 · 2023: $180 · 2024: $98.09 · 2025: $214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $492.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $491.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $282.33 | 2022-2025 | Mounjaro, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $243.66 | 2022 | |
| Amgen INC. | $178.92 | 2024-2025 | Evenity, Prolia |
| Corium, LLC | $133.73 | 2022-2025 | Azstarys |
| Servier Pharmaceuticals LLC | $131.68 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $124.97 | 2022 | |
| Glaxosmithkline, LLC. | $119.86 | 2021 | |
| Merck Sharp & Dohme LLC | $117.92 | 2022-2025 | Capvaxive, Gardasil 9 |
| Abbvie INC. | $114.59 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.37 | 2023 | Jardiance |
| Novo Nordisk INC | $40.12 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.44 | 2022 | |
| Neurocrine Biosciences, INC. | $32.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chimene Cobb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.